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MelanomaIn adoptive cell therapy (ACT), autologous tumor-speciﬁc T-cells isolated from cancer patients are activated
and expanded ex vivo, then infused back into the individual to eliminate metastatic tumors. A major
limitation of this promising approach is the rapid loss of ACT T-cell effector function in vivo due to the highly
immunosuppressive environment in tumors. Protection of T-cells from immunosuppressive signals can be
achieved by systemic administration of supporting adjuvant drugs such as interleukins, chemotherapy, and
other immunomodulators, but these adjuvant treatments are often accompanied by serious toxicities and
may still fail to optimally stimulate lymphocytes in all tumor and lymphoid compartments. Here we propose
a novel strategy to repeatedly stimulate or track ACT T-cells, using cytokines or ACT-cell-speciﬁc antibodies as
ligands to target PEGylated liposomes to transferred T-cells in vivo. Using F(ab′)2 fragments against a unique
cell surface antigen on ACT cells (Thy1.1) or an engineered interleukin-2 (IL-2) molecule on an Fc framework
as targeting ligands, we demonstrate that >95% of ACT cells can be conjugated with liposomes following a
single injection in vivo. Further, we show that IL-2-conjugated liposomes both target ACT cells and are capa-
ble of inducing repeated waves of ACT T-cell proliferation in tumor-bearing mice. These results demonstrate
the feasibility of repeated functional targeting of T-cells in vivo, which will enable delivery of imaging
contrast agents, immunomodulators, or chemotherapy agents in adoptive cell therapy regimens.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
Immunotherapy treatments stimulating a patient's own immune
system to attack tumors are beginning to show signs of clinical efﬁcacy,
demonstrating that the immune system can be harnessed for cancer
therapy even in patients with advanced disease [1–3]. Among many
immunotherapy strategies in development, adoptive cell therapy
(ACT) with autologous tumor-speciﬁc T-cells has shown particularly
striking results in recent phase I clinical trials [3,4]. In this approach,
autologous T-cells isolated from tumor biopsies or peripheral blooderms of the Creative Commons
permits non-commercial use,
the original author and source
sachusetts Avenue, Cambridge,
52 3293.
blished by Elsevier B.V. All rights reare treated with cytokine/stimulatory cocktails to promote expansion
of large numbers of tumor-reactive cells that can be reinfused into
the patient, following which the transferred cells can home to dissem-
inated tumor sites and destroy metastatic tumors. ACT therapy using
completely autologous patient-derived tumor-inﬁltrating lymphocytes
[4,5] or patient T-cells transduced with genetically engineered T-cell
receptors [3,6] (TCRs, either exogenous TCR chains or chimeric antigen
receptors composed of synthetic antigen-binding Ig domains fused
with TCR signaling components) have been demonstrated to elicit
objective response rates in up to 70% of patients with advanced meta-
static melanoma [4–7] and dramatic cures in chronic lymphoblastic
leukemia [3].
Despite these promising early clinical ﬁndings, efforts to increase
the fraction of patients showing complete responses (complete and
durable elimination of all detectable tumors) are needed. To this end,
a variety of strategies are being explored, including manipulation of
lymphocyte differentiation state during ex vivo expansion [8–10], com-
bination treatments where patients receive adjuvant drug therapiesserved.
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T-cells to express supporting costimulatory or cytokine genes
[12–14]. We recently demonstrated that the efﬁcacy of ACT can be dra-
matically enhanced by conjugation of cytokine- or drug-loaded
nanoparticles (NPs) to the surfaces of T-cells ex vivo prior to transfer
into tumor-bearing recipients [15,16], creating T-cell “pharmacytes”.
T-cell-bound particles provided pseudo-autocrine drug delivery to the
transferred cells that greatly increased the effective potency of adju-
vant drugs while simultaneously minimizing systemic exposure
to these potent supporting signals. This approach allowed autocrine
delivery of interleukin cytokines that dramatically enhanced the efﬁca-
cy of ACT T-cells in a metastatic melanomamodel [15] and the delivery
of immunosuppression-blocking drugs that enhanced expansion of
T-cells within large established tumors in a prostate cancer model [16].
A limitation of the pharmacyte approach is the one-time nature of
the intervention: ACT T-cells can only be loaded once with a cargo of
adjuvant drug prior to transfer, and the duration of stimulation is
inherently limited by expansion of the cell population in vivo, since
cell-bound particles are diluted with each cell division. We hypothe-
sized that a strategy to target supporting drugs to T-cells with nano-
particle drug carriers directly in vivo would enable transferred
lymphocytes to be repeatedly stimulated with supporting adjuvant
drugs, and thereby provide continuous supporting signals over the
prolonged durations that might be necessary for elimination of large
tumor burdens. Such “re-arming” of T-cells with supporting drugs
could be achieved by repeated administration of targeted particles,
allowing adoptively-transferred T-cells to be restimulated multiple
times directly in vivo, while the use of internalizing targeting ligands
would minimize the likelihood of immune responses against the
nanoparticle carrier. To our knowledge, only two prior studies have
attempted to target nanoparticles to T-cells in vivo [17,18]. In both
of these studies, particles were targeted to T-cells via peptide-MHC
ligands that bind to speciﬁc T-cell receptors. However, peptide-
MHC-functionalized nanoparticles have recently been shown to
deliver an anergizing/tolerizing signal to T-cells [18,19] — which is
ideal for treating graft rejection or autoimmunity, but runs counter
to the goals of cancer immunotherapy.
Here we report on initial results illustrating the feasibility of spe-
ciﬁcally targeting ACT T-cells in vivo using stimulatory or non-
stimulatory immunoliposomes. We synthesized and characterized
PEGylated liposomes conjugated with 2 types of targeting molecules:
(1) antibodies against unique cell surface antigens expressed only by
the ACT T-cells (here, we employ the congenic marker Thy1.1), mim-
icking unique surface markers introduced clinically in genetically-
engineered ACT T-cells [20,21]; and (2) recombinant interleukin-2
(IL-2), a cytokine that binds the trimeric IL-2 receptor (IL-2R)
expressed by activated T lymphocytes [22]. These two ligands provide
contrasting targeting strategies; anti-Thy1.1 provides highly speciﬁc
targeting without overt stimulation of target cells, while IL-2 provides
potentially less speciﬁc targeting (IL-2R can be expressed by some en-
dogenous T-cells) but also delivers a direct stimulatory signal to
T-cells. We characterized the efﬁcacy of targeting particles to anti-
tumor T-cells in vitro and internalization of liposomes triggered by
these ligands, and then analyzed targeting of ACT T-cells in vivo in
healthy animals and in a model of metastatic melanoma. Targeted
liposomes labeled T-cells in multiple systemic compartments in
vivo, with anti-Thy1.1 liposomes binding to >90% of transferred
cells following a single injection. Further, we demonstrate the proof
of concept that targeted stimulatory IL-2-liposomes can drive repeat-
ed expansion of ACT T-cells in vivo, following multiple periodic injec-
tions of targeted vesicles. We believe this strategy could provide a
safe means to amplify the efﬁcacy of ACT while avoiding systemic
toxicity associated with many adjuvant drug treatments, and would
be translatable to other immunotherapy settings, such as enhance-
ment of cancer vaccines and therapeutic interventions in infectious
diseases such as HIV.2. Material and methods
2.1. Materials
All lipids and polycarbonate membranes (0.2 μm) for size extru-
sion were from Avanti Polar Lipids (Alabaster, AL) and used as re-
ceived. DiD, ACK lysis buffer, Calcium Phosphate Transfection Kit,
HEK293 Free Style Cells, Max Efﬁciency® DH5α™ Competent cells
and Phoenix Eco viral packaging cells were obtained from Invitrogen
Life Technologies (Grand Island, NY). Anti-thy1.1 (clone 19E12) and
mouse IgG2a isotype control antibodies were purchased from BioXCell
(West Lebanon, NH). Dithiothreitol (DTT), Fluorescein isothiocyanate
(FITC) isomer I, Concanavalin A Type VI (ConA), and Triton X-100
were from Sigma-Aldrich (St. Louis, MO) and used as received.
Recombinant IL-2 and IL-7 were purchased from PeproTech (Rocky
Hill, NJ). Anti-mouse CD16/32, anti-CD25, anti-CD25-Alexa 488,
anti-CD8-PE, anti-Thy1.1, anti-Thy1.1-Percp-Cy5.5 and anti-Thy1.1-
FITC were from eBioscience (San Diego, CA). Anti-mouse vβ13 T-cell
Receptor-FITC was purchased from Becton Dickinson (Franklin
Lakes, NJ). Protein A agarose column and Amicon Ultra-15 30 kDa
MWCO Centrifugal Filter Units were from Millipore (Billerica, MA).
Polyethylenimine (PEI) was from Polysciences (Warrington, PA).
F(ab′)2 Preparation Kits, BCA Protein Assay Kits, and Zeba desalting
columns were from Pierce Thermo Scientiﬁc (Rockford, IL). IL-2
ELISA Kits were obtained from R&D Systems (Minneapolis, MN).
Ficoll-Pague Plus was from GE Health Care (Waukesha, WI).
EasySep™ Mouse CD8+ T Cell Enrichment Kit was from Stemcell
(Vancouver, BC, Canada). Collagenase II and Hank's Balanced Salt
Solution were purchased from (Gibco-Invitrogen, Carlsbad, CA).
EndoFree Plasmid Maxi Kit was from Qiagen (Valencia, CA).
Retronectin Recombinant Human Fibronectin Fragment was from
Clontech (Mountain View, CA). D-luciferin was from Caliper Life Sci-
ences (Hopkinton, MA). B16F10 melanoma cells were from American
Type Culture Collection (Manassas, VA). IL-2-Fc was a generous gift
from Dane Wittrup's lab at MIT.
2.2. Preparation of IL-2-Fc and anti-Thy1.1 F(ab′)2
IL-2-Fc is a bivalent fusion protein of the C-terminus of murine wild
type IL-2 linked to a mouse IgG2a backbone [23]. A D265A mutation
was introduced in the IgG2a Fc region to minimize interaction of
IL-2-Fc with Fc receptors [24]. IL-2-Fc gene was transformed into
DH5α cells via heat shock and extracted after clone expansion using
an EndoFree Plasmid Maxi Kit following the manufacturer's instruc-
tions. HEK293 Freestyle cells were transfected with IL-2-Fc gene/
polyethylenimine (PEI) complexes and grown in roller bottles at
37 °C for a week before harvest. Cells were spun down and secreted
IL-2-Fc in the supernatant was puriﬁed by gravity ﬂow/elution through
Protein A agarose columns and concentrated by using centrifugal ﬁlter
units (Amicon Ultra-15 30 kDa MWCO).
Monoclonal antibodies (Abs) against Thy1.1 were digested with
pepsin to generate the F(ab′)2 using a F(ab′)2 Preparation Kit following
the manufacturer's instructions. IL-2-Fc and anti-Thy1.1 F(ab′)2
concentrations were determined by the BCA Protein Assay Kit. IL-2-Fc
bioactivity concentration relative to wild type murine IL-2 was quanti-
ﬁed by an IL-2 ELISA Kit.
2.3. Synthesis of IL-2-Fc-liposomes and anti-Thy1.1-liposomes
Vacuum dried lipid ﬁlms composed of 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000
(maleimide-PEG2000-DSPE)/cholesterol/hydrogenated Soy L-α-phos-
phatidylcholine (HSPC) in a molar ratio of 2.5/27.5/69 together with
1% of a ﬂuorescent lipophilic tracer dye 1,1′-dioctadecyl-3,3,3′,3′-
Tetramethylindodicarbocyanine, 4-Chlorobenzenesulfonate Salt (DiD)
were rehydrated in 250 μl of 50 mM HEPES/150 mM NaCl-buffer
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vesicles and size extruded through a polycarbonate membrane
(0.2 μm). After washing in excess phosphate buffered saline (PBS)
pH7.4 and spinning down by ultracentrifugation at 110,000 ×g for
4 h, liposomes were re-suspended in 100 μl PBS/1.4 mg of lipids.
IL-2-Fc and anti-Thy1.1 F(ab′)2 were coupled to liposomes as previ-
ously described [23]. Brieﬂy, Ab or cytokine (4–8 mg/ml) was treated
with 1.8 mM DTT in the presence of 10 mM EDTA at 25 °C for
20 min to expose hinge region free thiols. DTT was subsequently
removed by using Zeba desalting columns before mixing with
maleimide-bearing liposomes (1 mg protein/1 mg lipid) in PBS pH
7.4. After incubation for 18 h at 25 °C on a rotator, excess protein
was removed by ultracentrifugation in excess PBS (if aggregation
occurs, liposomes were size extruded through a 0.2 μm polycarbonate
membrane at 37 °C before ultracentrifugation). Liposome sizes were
characterized before/after coupling by dynamic light scattering
(90Plus Particle Size Analyzer, Brookhaven, Holtsville, NY).
2.4. Quantiﬁcation of targeting ligands coupled to liposomes
Anti-Thy1.1-FITC was concentrated to 4–8 mg/ml using Ultra-15
Centrifugal Filters before coupling to liposomes as previously de-
scribed. After liposomes were solubilized in 2% Triton X-100 at
37 °C for 5 min with gentle vortexing, FITC ﬂuorescence was mea-
sured at ex/em wavelengths of 490/520 nm using a ﬂuorescence
plate reader (Tecan Systems, San Jose, CA) and converted to protein
concentrations using standard curves prepared from serial dilutions
of neat anti-Thy1.1-FITC stock solutions. IL-2-Fc-Lips were solubilized
in the same manner and the amount of IL-2 coupled was determined
using an IL-2 ELISA Kit (R&D Systems, Minneapolis, MN) following
the manufacturer's instructions.
2.5. Activation of pmel-1 Thy1.1+CD8+ T-cells
Animals were cared for in the USDA-inspected MIT Animal Facility
under federal, state, local and NIH guidelines for animal care. Spleens
from pmel-1 Thy1.1+mice were ground through a 70 μm cell strainer
and red blood cells were removed by incubating with ACK lysis buffer
(2 ml/spleen) for 5 min at 25 °C. After 1 wash in PBS, the remaining
cells were cultured at 37 °C in RPMI 1640 medium containing 10%
fetal calf serum (FCS). ConA at a ﬁnal concentration of 2 μg/ml and
IL-7 at 1 ng/ml were added to activate and expand splenocytes.
After two days, dead cells were removed by Ficoll-Pague Plus gradient
separation and CD8+ T-cells were isolated via magnetic negative
selection using an EasySep™ Mouse CD8+ T Cell Enrichment Kit.
Puriﬁed CD8+ T-cells were re-suspended at 1.5 × 106/ml RPMI
containing 10 ng/ml recombinant murine IL-2. After 24 h, cells were
washed 3 times in PBS and re-suspended in 100 × 106/ml for
adoptive transfer.
For bioluminescence imaging experiments, Click Beetle Red lucif-
erase (CBR-luc) [16] was introduced into pmel-1 T-cells (post Ficoll
puriﬁcation and magnetic selection) by retroviral transduction. Phoe-
nix Eco viral packaging cells were seeded at 4 × 106 cells/10 cm
tissue culture dish in 10 ml DMEM medium containing 10% FCS.
After incubation overnight at 37 °C, phoenix cells were exchanged
with 10 ml fresh DMEM with 10% FCS, transfected with CBR-luc
plasmid and Phoenix Eco plasmid using a Calcium Phosphate Trans-
fection Kit and cultured at 32 °C for 24 h. DMEM was then replaced
with 6 ml RPMI containing 10% FCS and transfected Phoenix Eco
cells were incubated for another 24 h. Supernatant containing the
retrovirus-packaged CBR-luc gene was collected and replaced with
fresh RPMI for another 24 h incubation. Supernatant was collected
again and combined with that collected 24 h earlier, and sterile
ﬁltered (0.45 μm). Six-well non-tissue culture plates (BD Falcon)
were coated with 1 ml RetroNectin (15 μg/ml) 18 h at 4 °C, then ex-
cess RetroNectin was aspirated. Pmel-1 T-cells post ﬁcoll puriﬁcationand magnetic selection were suspended in ﬁltered viral sups (RPMI
collected previously) with 10 ng/ml IL-2 at 1.8 × 106/ml, 3 ml was
added to each RetroNection-coated well, and spinoculation was
conducted by centrifuging at 2000 ×g for 1 h at 25 °C. Trans-
duced T-cells were then incubated at 37 °C. Six hours later, 1 ml
of fresh RPMI was added with 10 ng/ml IL-2. Transduced, ac-
tivated pmel-1 T-cells were used 1 day later for adoptive transfer
studies.2.6. In vitro liposome binding to T-cells
DiD-labeled protein-conjugated liposomes (0.7 mg lipids in
100 μl) were incubated with 15 × 106 activated pmel-1 Thy1.1+
T-cells in 1 ml complete RPMI supplemented with 10% FCS for
30 min at 37 °C with gentle agitation every 10 min. In competitive
conjugation assays, 100-fold molar excess soluble IL-2-Fc or
anti-Thy1.1 free antibody (compared to the amount coupled to lipo-
somes) was added 30 min before targeting liposomes to saturate
IL-2 or Thy1.1 receptors on the cells, respectively. For IL-2-
Fc-Liposome (IL-2-Fc-Lip) competition assays, 2.5 × 106 activated
pmel-1 CD8+ T-cells were mixed with 2.5 × 106 naïve C57Bl/6
splenocytes in 100 μl complete RPMI with 10% FCS. The cell mixture
was incubated with or without 0.24 mg/ml soluble IL-2-Fc, followed
by incubation with 0.07 mg/ml IL-2-Fc-Lip for 30 min at 37 °C with
total volume topped up to 300 μl. For competition assays with
anti-thy1.1.-liposome (anti-Thy1.1-Lip), 0.15 mg/ml liposomes (Lip)
were incubated with a mixture of 2.5 × 106 activated pmel-1 T-cells
and 2.5 × 106 naïve C57Bl/6 splenocytes (with or without pre-
blocking by 1.34 mg/ml anti-Thy1.1). Cells without any liposomes
added served as a control for cellular autoﬂuorescence and cells conju-
gated with 0.15 mg/ml IgG2a-liposomes (IgG2a-Lip) were used to test
non-speciﬁc binding of non-targeting liposomes. For all in vitro conju-
gation experiments, cells were stained with anti-CD8 and anti-Thy1.1
after two washes in ice cold PBS to remove unbound liposomes, and
analyzed by ﬂow cytometry on a BD FACS Canto except competition
assays which were done on a BD LSR II.2.7. Titration of liposome concentration for in vitro conjugation
Varying amounts of DiD-labeled anti-Thy1.1-Lip were added to
5 × 106 activated pmel-1 Thy1.1+ T-cells in 100 μl complete RPMI
with 10% FCS. The total volume for all groups was topped up with
RPMI with 10% FCS to 300 μl and incubated at 37 °C for 30 min. After
two washes in ice cold PBS to remove unbound liposomes, cells were
resuspended in FACS buffer, surface stained with ﬂuorescently labeled
anti-CD8 and anti-Thy1.1, and analyzed by ﬂow cytometry on a BD
LSR II.2.8. Internalization of liposomes
Anti-Thy1.1-Liposomes were labeled with 1% (mol) carboxy-
ﬂuorescein-1,2-dioleoyl-sn-glycero-3-phosphoethanolamine lipid (CF-
DOPE) instead of DiD during the synthesis stage and incubated with
6 × 106 activated pmel-1 Thy1.1+ T-cells/0.7 mg of lipids for 60 min
at 4 °C with gentle agitation every 15 min. After two washes in
ice cold PBS pH7.4 to remove unbound liposomes, T-cells were
resuspended in RPMI and aliquotted into four equal portions for 0, 2,
4 and 6 h time points, respectively. After each incubation interval at
37 °C, T-cells were washed 2× in ice cold PBS and re-suspended in
ﬂow cytometry buffer (2% FCS in PBS). Cells were placed on ice to min-
imize further internalization and analyzed by ﬂow cytometry on a BD
LSR II. Cells were also imaged directly without ﬁxation on a Zeiss LSM
510 laser scanning confocal microscope.
Fig. 1. T-cell-targeted liposome synthesis and characterization. (A) Schematic of
immunoliposome preparation. (B) Typical particle size distributions for liposomes before
antibody conjugation (open bars) and after conjugation (black ﬁlled bars) determined
by dynamic light scattering. (C) Quantiﬁcation of ligand (IL-2 cytokine equivalent
or anti-Thy1.1) coupled to liposomes incorporating different mole fractions of
maleimide-PEG lipid: 2.5% (black ﬁlled bar), 1% (open bar) or 0% (striped bar), assessed
by IL-2 ELISA and measuring FITC-labeled anti-Thy1.1 incorporation respectively.
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Albino C57BL/6 female mice 6–8 weeks of age were from the Jackson
Laboratory (Bar Harbor, ME). One day before adoptive transfer, mice
were sublethally lymphodepleted with 5 Gy total body irradiation.
15 × 106 activated pmel-1 CD8+ T-cells in 150 μl PBS were injected
intravenously (i.v.) into each recipient animal. DiD-labeled immuno-
liposomes (1.4 mg lipids)were re-suspended in 100 μl PBS and injected
i.v. immediately or three days after adoptive transfer. Twenty-four
hours after administration of liposomes, mice were euthanized and
blood, lymph node, and spleen cells were analyzed by ﬂow cytometry
on a BD FACS Canto to assess liposome binding to T-cells.
2.10. Adoptive transfer of CBR-Luc T-cells and bioluminescence imaging
B16F10 melanoma cells were suspended at 1 × 106 cells/200 μl in
Hank's Balanced Salt Solution and injected i.v. to induce lung metas-
tases in albino C57Bl/6 mice (day−8). Animals were then sublethally
lymphodepleted by total body irradiation (5 Gy) 7 days post tumor
inoculation (day −1). Pmel-1 CD8+ T-cells transduced with CBR-
Luc (12 × 106) were resuspended in 150 μl PBS and administered
i.v. one day after lymphodepletion (day 0). IL-2-Fc-Lip (1 mg of
liposomes) or PBS was injected i.v. immediately after ACT and on
day 6. D-Luciferin, a substrate for CBR-luc, was suspended in PBS
(15 mg/ml) and 150 mg luciferin/kg body weight was injected Intra-
peritoneally (i.p.) in anesthetized animals 10 min before biolumines-
cence imaging acquisitions (5 min, 3 min, 2 min and 1 min) on a
Xenogen IVIS Spectrum Imaging System (Caliper Life Sciences).
Images were collected every two days starting from day 0 (2 h after
ACT) to day 14. Living Image software version 3.0 (Caliper Life
Sciences) was used to acquire and quantitate the bioluminescence
imaging data sets. To compare the stimulatory effects of soluble IL-2
and IL-2-Fc-Lip, a similar experiment was repeated with 1st/2nd
dose as 0.5 mg/1 mg IL-2-Fc-Lip or 10 μg/20 μg soluble recombinant
wild type mouse IL-2 (PeproTech, Rocky Hill, NJ), equivalent to the
amount of IL-2 coupled on IL-2-Fc-Lip). On day 12 mice were
sacriﬁced and T-cells from inguinal lymph nodes were collected and
surface stained for CD8 and vβ13 before analyzing by ﬂow cytometry
on a BD FACS Canto to assess the percentage of tumor-speciﬁc T-cells
in each group.
2.11. Sample preparation for ﬂow cytometry
Inguinal lymph nodes and spleens were ground through a 70 μm
cell strainer and washed once with ice cold PBS. Splenocytes were
then lysed with ACK lysis buffer (2 ml/spleen) for 5 min at 25 °C to
remove red blood cells before washing in ice cold PBS. Blood samples
were lysed 2× with 1 ml ACK lysis buffer for 5 min at 25 °C and then
washed 1× with ice cold PBS. All cells were washed in FACS buffer
(PBS with 2% Fetal Calf Serum) once before surface-staining with
Ab. After staining, cells were washed 2× in FACS buffer and analyzed
on a BD FACS Canto Flow Cytometer. All data were processed using
FlowJo software.
2.12. Statistical analysis
Statistical analysis was done using GraphPad Prism software
and two-tailed unpaired t-tests were conducted between groups of
experimental data. Graphs show the mean ± SEM of sample groups.
3. Results and discussion
3.1. Synthesis and characterization of IL-2-Fc-Lip and anti-Thy1.1-Lip
To generate cytokine- or antibody (Ab)-conjugated liposomes
(IL-2-Fc-Lip or anti-Thy1.1-Lip) for T-cell targeting, PEGylated
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PEG-DSPE) were prepared from high-Tm lipids and sized by
membrane ﬁltration to a mean diameter of 173 ± 13 nm (Fig. 1A,
B). Murine IL-2 fused to the C-terminus of mouse IgG2a Fc or
anti-Thy1.1 F(ab′)2 were coupled to the maleimide termini of PEG
chains to serve as targeting ligands of the immunoliposomes. To min-
imize interaction of liposomes with phagocyte Fc receptors, a D265A
mutation was introduced in the Fc portion of IL-2-Fc [24] and F(ab′)2
fragments of anti-Thy1.1 monoclonal antibodies were generated by
pepsin digestion. Prior to F(ab′)2/cytokine coupling, IL-2-Fc and
anti-Thy1.1 F(ab′)2 weremildly reduced by DTT to expose hinge region
free thiols for reaction with the liposome maleimide functional head
groups. We tested liposomes containing two different mole fractions
of maleimide-PEG lipid (1 or 2.5 mol% of total lipids), and found greater
targeting ligand conjugation with higher fractions of maleimide-lipid,
as expected (Fig. 1C). Negligible IL-2 or F(ab′)2 binding to liposomes
was observed in the absence of the maleimide reactive groups.
Liposomes with 2.5 mol% mal-PEG-DSPE gave 23 ± 2 μg of IL-2
(cytokine equivalent, or 1.4 nmol IL-2) or 76 ± 7 μg of anti-Thy1.1
(0.5 nmol F(ab′)2)/mg lipid after overnight coupling at 25 °C. As
shown in Fig. 1B, targeting ligand conjugation caused a slight increase
in the mean size of the vesicles from 173 ± 13 nm to 186 ± 16 nm.
3.2. IL-2-Fc-Lip and anti-Thy1.1-Lip binding to T-cells in vitro
To generate a target population of T-cells to be used in adoptive
transfer studies, CD8+ T-cells from pmel-1 Thy1.1+ mice (which
express a transgenic T-cell receptor speciﬁc for the gp100 antigen of
melanoma [25]) were isolated by magnetic negative selection from
activated splenocytes, and expanded by culturing with IL-2 for
1 day to obtain an elevated expression of CD25 (the α-chain of the
trimeric IL-2 receptor) compared to naive pmel-1 or naive polyclonal
C57Bl/6 CD8+ T-cells (Fig. 2A and data not shown). Fluorescently
labeled PEGylated vesicles showed very low background binding to
activated pmel-1 T-cells following a 30 min incubation at 37° in vitro,
but IL-2-Fc-Lip or anti-Thy1.1-Lip containing 1% or 2.5% maleimide
functional groups efﬁciently bound to activated pmel-1 T-cells
(Fig. 2B). The Mean Fluorescence Intensities (MFI) of cells after conju-
gation with different types of liposomes was quantiﬁed; the high ex-
pression levels of Thy1.1 on pmel-1 T-cells led to much greater
per-cell binding of anti-Thy1.1-Lip vs. IL-2-Fc-Lip (Fig. 2C). For both
targeting ligands, liposomes containing 2.5 mol% mal-PEG-DSPE (and
therefore with higher ligand densities) achieved much greater binding
to T-cells than vesicles with 1 mol% of themaleimide lipid, withMFIs of
bound liposomes increased by 6-fold and 4-fold for anti-Thy1.1-Lip and
IL-2-Fc-Lip, respectively (Fig. 2B, C).
To evaluate the speciﬁcity of anti-Thy1.1-Lip and IL-2-Fc-Lip bind-
ing, we assessed T-cell labeling in the presence of competing free
IL-2-Fc or anti-Thy1.1 Abs added to a 1:1 mixture of naïve C57Bl/6 lym-
phocytes and pmel-1 T-cells 30 min before the targeted vesicles.
IL-2-Fc-Lip bound to activated pmel-1 T-cells, but not naïve C57Bl/6
CD8+ T cells that lack IL-2 receptors (Fig. 2D middle left). Pre-
blocking pmel-1 T-cells with soluble IL-2-Fc blocked 90% of binding
to pmel-1 T-cells (Fig. 2Dmiddle right, E). Similarly, anti-Thy1.1-Lip se-
lectively targeted pmel-1 CD8+ T cells but not naive C57Bl/6 (Thy1.2+)Fig. 2. In vitro binding of IL-2-Fc-Lip and anti-thy1.1 F(ab′)2-Lip to primary T-cells. (A) Flo
(Thy1.1-) splenocytes vs. activated pmel-1 Thy1.1+CD8+ T-cells. (B, C) Pmel-1 CD8+ Thy1
(IL-2-Fc or anti-Thy1.1 F(ab′)2 conjugated) for 30 min at 37 °C in complete RPMI, then analy
scatter plots (B) and quantiﬁcation of Mean Fluorescence Intensity (MFI) of pmel-1 T-cells
pmel-1 CD8+ T-cells were mixed with naive C57BL/6 splenocytes in a 1:1 ratio and incu
then analyzed by ﬂow cytometry. (D) Shown are scatter plots representing liposome ﬂuor
(Thy1.1+) with/without 0.24 mg/ml soluble IL2-Fc or 1.34 mg/ml anti-Thy1.1 antibody
IgG2a-lipo are also shown. (E) Quantiﬁcation of the MFI of Pmel-1 CD8+ T cells when boun
of ﬂuorescent liposomes were added to 5 × 106 activated pmel-1 T-cells and incubated at 37
*, p b 0.05; **, p b 0.01; ***, p b 0.001.CD8+ T cells (Fig. 2D bottom left). Pre-incubation of pmel-1 T-cells
with anti-Thy1.1 lowered anti-Thy1.1-Lip binding by 99% (Fig. 2D
bottom right, E). Autoﬂuorescence and non-speciﬁc binding of
non-targeted control IgG2a-Lip were negligible (Fig. 2D top left and
right, E). As expected from the pM afﬁnity of IL-2 for its receptor
[26,27] and the typical nM afﬁnity of commercial antibodies, liposomes
at concentration of 0.4 mg/ml (equivalent to 2 nM of liposomes)
labeled 100% of activated pmel-1 T-cells in vitro, and liposome binding
reached a plateau at concentrations higher than 0.4 mg/ml (equivalent
to 2 nM liposomes) (Fig. 2F). Thus, both IL-2- and anti-Thy1.1-targeted
stealth liposomes achieve speciﬁc and avid binding to primed pmel-1
CD8+ T-cells. Even when the concentration was titrated down to
0.1 mg/ml, nearly 100% of cells were still labeled with liposomes, albeit
with fewer liposomes bound per cell.
3.3. Internalization of Anti-Thy1.1-conjugated liposomes
We previously reported that IL-2-Fc-conjugated liposomes are
rapidly internalized by activated T-cells in vitro [28]. To determine
whether anti-Thy1.1-Lip would also trigger liposome endocytosis,
we added anti-Thy1.1-Lip incorporating a carboxyﬂuorescein (CF)-
headgroup lipid to pmel-1 T-cells at 4 °C to allow binding
without internalization, then warmed the cells to 37 °C and assessed
cell-associated ﬂuorescence over time. Fluorescein has highly pH-
sensitive ﬂuorescence that is strongly quenched at acidic pHs [29].
The high avidity of liposome binding to cells led to no measurable re-
lease of free liposomes into the supernatant over 6 h at 37 °C (not
shown); we thus attributed loss of the CF tracer signal to endocytic
uptake by labeled cells. Over a time course of 6 h, the MFI of
liposome-labeled T-cells steadily dropped, corresponding to roughly
90% internalization over this time course (Fig. 3A). Confocal imaging
also showed that anti-Thy1.1-Lip ﬂuorescence initially localized to
the plasma membrane of labeled cells was largely lost by 6 h
(Fig. 3B).
3.4. In vivo targeting of IL-2-Fc-Lip and anti-Thy1.1-Lip in healthy
animals
Next, we tested the capacity of anti-Thy1.1-Lip and IL-2-Fc-Lip to
target pmel-1 T-cells in vivo in healthy mice. PEGylated liposomes con-
jugated with isotype control murine IgG2a were prepared to serve as a
control non-T-cell-targeting liposome. Tomodel clinical adoptive T-cell
therapy, recipient Thy1.2+ C57Bl/6 mice were lymphodepleted by sub-
lethal irradiation, followed by i.v. injection of 15 × 106 activated
pmel-1 Thy1.1+CD8+ T-cells one day later. Lymphodepletion removes
cytokine sinks and regulatory T-cells to allow more efﬁcient expansion
and effector function of transferred T-cells [30,31]. To assess T-cell
targeting, IgG2a-Lip, IL-2-Fc-Lip, or anti-Thy1.1-Lip ﬂuorescently
labeled with the non-pH-sensitive tracer DiD were injected i.v. either
immediately after adoptive transfer or 3 days after T-cell injection.
Twenty-four hours after liposome injection, cells from the blood,
lymph nodes (LNs), and spleens were analyzed by ﬂow cytometry to
assess binding of ﬂuorescent liposomes (Fig. 4A). Thy1.1 expression
allowed liposome binding to transferred pmel-1 T-cells to be distin-
guished from endogenous T-cells (Fig. 4B). Sample ﬂow cytometryw cytometry analysis of cell surface expression of CD25 and Thy1.1 on naïve C57BL6/J
.1+ T-cells were incubated with 0.7 mg/ml (per 15 × 106 cells) DiD-labeled liposomes
zed by ﬂow cytometry for liposome binding. Shown are representative ﬂow cytometry
as a function of mol% of mal-PEG-DSPE included in the vesicles (C). (D, E) Activated
bated with 0.07 mg/ml IL2-Fc-Lip or 0.15 mg/ml anti-Thy1.1-Lip for 30 min at 37 °C,
escence on naive C57BL/6 CD8+ T cells (Thy1.1−) and activated pmel-1 CD8+ T-cells
added for 30 min prior to addition of liposomes. Cells incubated with 0.15 mg/ml
d with respective liposomes or pre-blocked by free Ab/IL-2. (F) Titrated concentrations
°C for 30 min, then analyzed by ﬂow cytometry for MFI of T-cell-associated liposomes.
431Y. Zheng et al. / Journal of Controlled Release 172 (2013) 426–435histograms are shown in Fig. 4C, illustrating conjugation efﬁciencies of
IgG2a-Lip, IL-2-Fc-Lip, and anti-Thy1.1-Lip obtained when liposomes
were injected immediately after ACT T-cells. The percentage endoge-
nous or ACT CD8+ T-cells labeled by each type of liposome in theblood (Fig. 4D), lymph nodes (Fig. 4E) and spleens (Fig. 4F) were
assessed; this analysis revealed that IgG2a-Lip exhibited low binding
to both T-cell populations. In contrast, anti-Thy1.1-Lip labeled nearly
100% of the transferred T-cells in the blood and spleen whether
Fig. 3. Internalization of Thy1.1-targeted liposomes. Carboxy-ﬂuorescein (CF)-labeled
anti-Thy1.1-Lip (1.4 mg/ml) were incubated with 12 × 106 activated pmel-1 CD8+
T-cells in 500 μl RPMI containing 10% FCS for 1 h at 4 °C, washed, then incubated in
RPMI at 37 °C until analysis by ﬂow cytometry 2 h, 4 h or 6 h later. (A) MFI of
T-cell-associated CF ﬂuorescence. (B) Confocal images of cells at time zero or after
6 h at 37 °C. Scale bar = 20 μm.
432 Y. Zheng et al. / Journal of Controlled Release 172 (2013) 426–435injected on day 0 or day 3. The slightly greater background binding of
isotype control IgG2a-Lip to ACT vs. endogenous T-cells in spleens
was found to be an artifact of the liposome dose; injection of lower li-
posome doses of 0.18 mg (approximately ~0.1 mg/ml liposomes in the
blood) led to a similar efﬁciency of speciﬁc T-cell binding but eliminat-
ed the low differential background binding to ACT vs. endogenous
T-cells (data not shown). A lower fraction of T-cells in lymph nodes
were labeled by anti-Thy1.1-Lip following a day 3 injection, which
may reﬂect a combination of poor entry of targeted liposomes into
LN and/or incomplete recirculation of T-cells from LN back into the
blood in the 24 h time window between liposome injection and our
analysis. Anti-Thy1.1-Lip also showed low levels of background binding
to endogenous (Thy1.1−) T-cells. IL-2-Fc-Lip labeled the majority of
pmel-1 T-cells in the LNs, spleen and blood when injected just after
T-cells, and also showed relatively low binding to endogenous T-cells.
However, injection of IL-2Fc-Lip on day 3 led to relatively poor T-cell
labeling in the blood and LNs, while still labeling a majority of ACT
T-cells in the spleen. Poor labeling by IL-2-Fc-Lip on day 3 reﬂected
rapid downregulation of the IL-2R in vivo following T-cell transfer in
the absence of antigen (data not shown). Thus, both IL-2-Fc and
anti-Thy1.1 F(ab′)2 can be effective for speciﬁcally targeting adoptively
transferred T-cells in vivo, though modulation of IL-2R levels by T-cells
over time is an important consideration for achieving effective
targeting.3.5. IL-2-Fc-Lip permit repeated boosting of ACT T-cells in a murine lung
metastasis model
To test the potential functional impact of stimulatory T-cell
targeted liposomes, we assessed the response of pmel-1 melanoma-
speciﬁc T-cells in vivo during ACT treatment of B16F10 tumors in a
metastatic lung tumor model. B16F10 melanoma cells were injected
via the tail vein to allow lung metastases to establish for 10 days,
then animals were lymphodepleted and received adoptive transfer
of luciferase-expressing pmel-1 melanoma-speciﬁc CD8+ T-cells
(Fig. 5A). In one group of animals, T-cell expansion was followed
over time by bioluminescence imaging without further treatment,
while in other two groups of mice, the adoptively-transferred cells
were boosted on days 0 and 6 by injection of IL-2-Fc-Lip. Adoptively
transferred cells without further adjuvant support showed a low
level persistence in the tumor-bearing recipients that gradually
declined over 14 days, as expected in the absence of additional stim-
ulation or protection from tumor immunosuppression [25] (Fig. 5B,
C). In contrast, following injection of the ﬁrst dose of IL-2-Fc-Lip,
pmel-1 T-cells expanded 3-fold more than the control T-cell therapy
group. These boosted T-cells began to contract again between day 4
and day 6, but following a second dose of IL-2-Fc-Lip, re-expanded
to an even greater level, reaching a peak by day 10 with 6-fold greater
T-cell numbers relative to the T-cell-only treatment group (Fig. 5B, C).
To assess the relative potency of stimulation achieved by IL-2-Fc-Lip
compared to traditional systemic IL-2 therapy, we repeated this ACT
experiment and compared the expansion of T-cells following
injection of IL-2-Fc-Lip or soluble IL-2 (at an equivalent total amount
of cytokine to that bound to the liposomes) on day 0 and day 6. Flow
cytometry analysis of T-cells pooled from the inguinal lymph nodes
12 days after adoptive transfer conﬁrmed that the frequency of
tumor-speciﬁc CD8+ T-cells (pmel-1 T-cells express the Vβ13 TCR β
chain) was nearly 3 times greater in animals that received
IL-2-Fc-Lip injections compared to T-cells alone (Fig. 5D–E). Further,
soluble IL-2 at these doses showed no enhancement in T-cell expan-
sion. The difference between the potency of IL-2-Fc-Lip and soluble
IL-2 may reﬂect the very short half-life of IL-2 in vivo [32], which
the PEGylated liposomes may partly overcome. Notably, this en-
hanced potency was not accompanied by overt toxicity as assessed
by changes in animal weights during the therapy (data not shown).
Thus, IL-2-targeted liposomes allow multiple boosts of ACT T-cells in
vivo, leading to repeated waves of T-cells expansion in tumor-
bearing animals, which exceed the response elicited by systemic
free IL-2.4. Conclusions
Here we synthesized and characterized antibody- and cytokine-
decorated immunoliposomes targeting unique cell surface antigens
or activation markers on T-cells, respectively. Targeting liposomes
bound to ACT T-cells speciﬁcally in vitro, and further, anti-
Thy1.1-Lip also labeled nearly 100% of transferred T-cells in systemic
compartments and most of transferred T-cells in LN in vivo following
a single injection of targeted vesicles. Despite its lower targeting
speciﬁcity compared to anti-Thy1.1-Lip, IL-2-Fc-Lip was able to re-
peatedly boost transferred T-cells in vivo in tumor-bearing animals
and provide direct stimulation to ACT T-cells. We focused here on
an initial characterization of in vitro and in vivo T-cell targeting, and
future work will examine the therapeutic efﬁcacy of ACT cell
targeting with drug-loaded liposomes. However, these results dem-
onstrate the concept of repeated targeting of ACT T-cells for adjuvant
stimulation in vivo. This data sets the stage for functional targeting of
supporting adjuvant drugs or imaging contrast agents to T-cells, in
order to enhance the efﬁcacy of ACT and/or permit longitudinal track-
ing of ACT T-cells in vivo.
Fig. 4. IL-2-Fc- and anti-Thy1.1-Liposomes target transferred T-cells in vivo. C57Bl/6 mice received i.v. adoptive transfer of 15 × 106 pmel-1 CD8+Thy1.1+ T-cells, followed by i.v. injec-
tion of 1.4 mg IL-2-Fc-Lip, anti-Thy1.1-Lip, or isotype control IgG2a-Lip either immediately after the T-cells or 3 days after the T-cells. Liposome binding to cells recovered from lymphoid
organs and blood was analyzed 24 h after liposome injections by ﬂow cytometry. (A) Timeline of injections and analysis. (B) Representative ﬂow cytometry plots illustrating gating
strategy for analysis of liposome binding to transferred pmel-1 T-cells or endogenous CD8+ T-cells. (C) Representative histograms of pmel-1 T-cell or endogenous CD8+ T-cell labeling
following day 0 liposome injections. (D–F) Quantiﬁcation of percentages of endogenous or transferred T-cells labeled by day 0 or day 3 liposome injections in the blood (D), lymph nodes
(E), and spleen (F). n = 5 animals/group for IgG2a-Lip and anti-Thy1.1-Lip and n = 3 for IL-2-Fc-Lip. *, p b 0.05; **, p b 0.01; ***, p b 0.001.
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Fig. 5. IL-2-Fc-liposomes allow repeated expansion of target ACT T-cells in vivo in tumor-bearing animals. (A–C) B16F10 tumor cells (1 × 106) were injected i.v. into albino C57Bl/6 mice
and allowed to establish lung metastases for 7 days. Animals were then sublethally lymphodepleted by irradiation and received i.v. adoptive transfer of 12 × 106 luciferase-expressing
pmel-1 CD8+ T-cells the next day. One group of mice additionally received injections of IL-2-Fc-Lip (1 mg, carrying 60 μg IL-2-Fc or 20 μg IL-2 cytokine equivalent) i.v. immediately after
T-cell transfer and again on day 6. (A) Timelines of cell/liposome injections and bioluminescence imaging of T-cells. (B) Representative bioluminescent images of ACT T-cells over time.
(C) Quantiﬁcation of average whole-body T-cell bioluminescence over time. (D–E) Groups of C57B/6 mice with established lung metastases were left untreated or were treated with
T-cells as in A, then received either IL-2-Fc-Lip or equivalent total doses of systemic free IL-2 (10 μg day 0, 20 μg day 6) injected i.v. on day 0 and day 6. (D) Sample ﬂow cytometry
analyses showing percentages of tumor-speciﬁc (vβ13 TCR+) CD8+ T-cells among T-cells in inguinal lymph nodes on day 12 after adoptive transfer. (E) Quantiﬁcation of average
frequency of tumor-speciﬁc (vβ13 TCR+) CD8+ T-cells in inguinal lymph nodes 12 days after adoptive transfer. n = 3–4 animals/group. *, p b 0.05; **, p b 0.01.
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